Table 3 Characteristics of long-term survivors.
Alive at 3 years (n = 15) | Alive at 5 years (n = 10) | |
|---|---|---|
Age (years), median (range) | 38 (25–68) | 51.5 (26–68) |
Sex | ||
Female | 7 (46.7) | 5 (50) |
Male | 8 (53.3) | 5 (50) |
Time from diagnosis to inclusion | 49 (0–225) | 43.5 (0–198) |
Time from enrollment to transplant | 25 (7–155) | 19.5 (7–155) |
Previous auto HSCT | 1 (6.7) | 0 |
Clinical history | ||
Primary refractory | 9 (60) | 6 (60) |
Relapsed | 6 (40) | 4 (40) |
Diagnosis | ||
Acute Myeloid Leukemia | 14 (93.3) | 9 (90.0) |
de novo | 11 (78.6) | 7 (77.8) |
Secondary | 3 (21.4) | 2 (22.2) |
Therapy-related | 0 | 0 |
Acute Lymphoblastic Leukemia | 1 (6.7) | 1 (10.0) |
de novo | 1 (100) | 1 (100) |
Secondary | 0 | 0 |
B-lineage | 1 (100) | 1 (100) |
T- lineage | 0 | 0 |
Ph pos | 1 (100) | 1 (100) |
Cytogenetics | ||
Low risk | 0 | 0 |
Intermediate risk | 9 (60) | 6 (60) |
High risk | 5 (33.3) | 3 (30) |
Unknown | 1 (6.7) | 1 (10) |
Molecular biology | ||
BCR-ABL mutated | 1/13 (7.7) | 1 (11.1) |
AF4-MLL mutated | 0/1 | 0 |
AML1 ETO mutated | 0/12 | 0 |
FLT3-ITD mutated | 2/12 (16.7) | 1 (12.5) |
CEBPA mutated | 0/12 | 0 |
NPM1 mutated | 4/12 (33.3) | 3 (37.5) |
MLL-PTD mutated | 0/12 | 0 |
Sorror score | ||
0 | 11 (73.3) | 8 (80) |
1 | 4 (26.7) | 2 (20) |
2 | 0 (0) | 0 (0) |
3 | 0 (0) | 0 (0) |
>3 | 0 (0) | 0 (0) |
Blasts PB % at enrollment | 15 (0–60) | 23.5 (0–60) |
Platelets ×109/L at enrollment | 44 (3–242) | 40 (12–242) |
Ferritin ng/mL at enrollment | 1480 (624–3019) | 1031 (624–2556) |
Albumin, g/L at enrollment | 4.6 (3.2–45) | 4.4 (3.5–45) |
Donor type | ||
URD | 7 (46.7) | 4 (40) |
10/10 matched | 5 (71.4) | 4 (100) |
mis-matched | 2 (28.6) | 0 |
CB | 1 (6.7) | 1 (10) |
Haploidentical | 7 (46.7) | 5 (50) |
Female donor for male recipient | 4 (26.7) | 2 (20) |
HSC source | ||
PBSC | 6 (40) | 4 (40) |
BM | 8 (53.3) | 5 (50) |
CB | 1 (6.7) | 1 (10) |
CMV serostatus | ||
R CMV+/D CMV+ | 6 (42.9) | 3 (33.3) |
R CMV+/D CMV− | 6 (42.9) | 4 (44.4) |
R CMV−/D CMV+ | 1 (7.1) | 1 (11.1) |
R CMV−/D CMV− | 1 (7.1) | 1 (11.1) |
Acute GvHD | 7 (46.7) | 4 (40) |
Chronic GvHD | 2 (13.3) | 1 (10) |
